Mucin-like peptides from Echinococcus granulosus induce antitumor activity

Noya,Verónica; Bay,Sylvie; Festari,María   Florencia; García,Enrique  P.; Rodriguez,Ernesto; Chiale,Carolina; Ganneau,Christelle; Baleux,Françoise; Astrada,Soledad; Bollati-Fogolín,Mariela; Osinaga,Eduardo; Freire,Teresa

doi:10.3892/ijo.2013.2000

Mucin-like peptides from Echinococcus granulosus induce antitumor activity

Authors:
- Verónica Noya
- Sylvie Bay
- María Florencia Festari
- Enrique P. García
- Ernesto Rodriguez
- Carolina Chiale
- Christelle Ganneau
- Françoise Baleux
- Soledad Astrada
- Mariela Bollati-Fogolín
- Eduardo Osinaga
- Teresa Freire
View Affiliations

Affiliations: Department of Immunobiology, School of Medicine, UdelaR, 11800 Montevideo, Uruguay, Department of Structure and Chemical Biology, Unit of Biomolecule Chemistry, Institut Pasteur, 75724 Paris Cedex 15, France, Cell Biology Unit, Institut Pasteur Montevideo, Mataojo 2020, 11400 Montevideo, Uruguay
Published online on: June 28, 2013 https://doi.org/10.3892/ijo.2013.2000
Pages: 775-784

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

There is substantial evidence suggesting that certain parasites can have antitumor properties. We evaluated mucin peptides derived from the helminth Echinococcus granulosus (denominated Egmuc) as potential inducers of antitumor activity. We present data showing that Egmuc peptides were capable of inducing an increase of activated NK cells in the spleen of immunized mice, a fact that was correlated with the capacity of splenocytes to mediate killing of tumor cells. We demonstrated that Egmuc peptides enhance LPS-induced maturation of dendritic cells in vitro by increasing the production of IL-12p40p70 and IL-6 and that Egmuc-treated DCs may activate NK cells, as judged by an increased expression of CD69. This evidence may contribute to the design of tumor vaccines and open new horizons in the use of parasite-derived molecules in the fight against cancer.

View Figures

View References

1	Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
2	de Martel C, Ferlay J, Franceschi S, et al: Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 13:607–615. 2012.PubMed/NCBI
3	Benamrouz S, Conseil V, Creusy C, Calderon E, Dei-Cas E and Certad G: Parasites and malignancies, a review, with emphasis on digestive cancer induced by Cryptosporidium parvum (Alveolata: Apicomplexa). Parasite. 19:101–115. 2012. View Article : Google Scholar : PubMed/NCBI
4	Oliveira EC, Leite MS, Miranda JA, et al: Chronic Trypanosoma cruzi infection associated with low incidence of 1,2-dimethylhydrazine-induced colon cancer in rats. Carcinogenesis. 22:737–740. 2001.
5	Chen L, He Z, Qin L, et al: Antitumor effect of malaria parasite infection in a murine Lewis lung cancer model through induction of innate and adaptive immunity. PLoS One. 6:e244072011. View Article : Google Scholar : PubMed/NCBI
6	Wang XL, Fu BQ, Yang SJ, et al: Trichinella spiralis - a potential antitumor agent. Vet Parasitol. 159:249–252. 2009. View Article : Google Scholar
7	Akgül H, Tez M, Unal AE, Keşkek M, Sayek I and Ozçelik T: Echinococcus against cancer: why not? Cancer Immunol Immunother. 98:1999–2000. 2003.
8	Darani HY and Yousefi M: Parasites and cancers: parasite antigens as possible targets for cancer immunotherapy. Future Oncol. 8:1529–1235. 2012. View Article : Google Scholar : PubMed/NCBI
9	Yousofi Darani H, Soozangar N, Khorami S, Taji F, Yousofi M and Shirzad H: Hydatid cyst protoscolices induce cell death in WEHI-164 fibrosarcoma cells and inhibit the proliferation of baby hamster kidney fibroblasts in vitro. J Parasitol Res. 304183:January 31–2012. View Article : Google Scholar
10	Medzhitov R: Recognition of microorganisms and activation of the immune response. Nature. 449:819–826. 2007. View Article : Google Scholar : PubMed/NCBI
11	Palucka AK, Ueno H, Fay JW and Banchereau J: Taming cancer by inducing immunity via dendritic cells. Immunol Rev. 220:129–150. 2007. View Article : Google Scholar : PubMed/NCBI
12	Correale J and Farez M: Helminth antigens modulate immune responses in cells from multiple sclerosis patients through TLR2-dependent mechanisms. J Immunol. 183:5999–6012. 2009. View Article : Google Scholar : PubMed/NCBI
13	Elliott DE and Weinstock JV: Helminth-host immunological interactions: prevention and control of immune-mediated diseases. Ann NY Acad Sci. 1247:83–96. 2012. View Article : Google Scholar : PubMed/NCBI
14	van Vliet SJ, van Liempt E, Saeland E, et al: Carbohydrate profiling reveals a distinctive role for the C-type lectin MGL in the recognition of helminth parasites and tumor antigens by dendritic cells. Int Immunol. 17:661–669. 2005.PubMed/NCBI
15	Vanhoutte F, Breuilh L, Fontaine J, et al: Toll-like receptor (TLR)2 and TLR3 sensing is required for dendritic cell activation, but dispensable to control Schistosoma mansoni infection and pathology. Microbes Infect. 9:1606–1613. 2007. View Article : Google Scholar : PubMed/NCBI
16	Cummings RD and Nyame AK: Schistosome glysoconjugates. Biochim Biophys Acta. 1455:363–374. 1999. View Article : Google Scholar : PubMed/NCBI
17	Doedens A, Loukas A and Maizels RM: A cDNA encoding Tc-MUC-5, a mucin from Toxocara canis larvae identified by expression screening. Acta Trop. 79:211–217. 2001. View Article : Google Scholar : PubMed/NCBI
18	Theodoropoulos G, Hicks SJ, Corfield AP, Miller BG and Carrington SD: The role of mucins in host-parasite interactions: Part II - helminth parasites. Trends Parasitol. 17:130–135. 2001. View Article : Google Scholar : PubMed/NCBI
19	Thomas PG and Harn DAJ: Immune biasing by helminth glycans. Cell Microbiol. 6:13–22. 2004. View Article : Google Scholar : PubMed/NCBI
20	Alvarez Errico D, Medeiros A, Míguez M, et al: O-glycosylation in Echinococcus granulosus: identification and characterization of the carcinoma-associated Tn antigen. Exp Parasitol. 98:100–109. 2001.
21	Brockhausen I: Mucin-type O-glycans in human colon and breast cancer: glycodynamics and functions. EMBO Rep. 7:599–604. 2006.
22	Schietinger A, Philip M, Yoshida BA, Azadi P, Liu H, Meredith SC and Schreiber H: A mutant chaperone converts a wild-type protein into a tumor-specific antigen. Science. 314:304–308. 2006. View Article : Google Scholar : PubMed/NCBI
23	Baldus SE, Engelmann K and Hanisch FG: MUC1 and the MUCs: a family of human mucins with impact in cancer biology. Crit Rev Clin Lab Sci. 41:189–231. 2004. View Article : Google Scholar : PubMed/NCBI
24	Carraway KL III, Funes M, Workman HC and Sweeney C: Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Top Dev Biol. 78:1–22. 2007. View Article : Google Scholar : PubMed/NCBI
25	Freire T and Osinaga E: The sweet side of tumor immunotherapy. Immunotherapy. 4:719–734. 2012. View Article : Google Scholar : PubMed/NCBI
26	Kufe DW: Mucins in cancer: function, prognosis and therapy. Nat Rev Cancer. 9:874–885. 2009. View Article : Google Scholar : PubMed/NCBI
27	Beatson RE, Taylor-Papadimitriou J and Burchell JM: MUC1 immunotherapy. Immunotherapy. 2:305–327. 2010. View Article : Google Scholar
28	Quoix E, Ramlau R, Westeel V, et al: Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 12:1125–1133. 2011. View Article : Google Scholar : PubMed/NCBI
29	Slovin SF, Ragupathi G, Musselli C, et al: Fully synthetic carbohydrate-based vaccines in biochemically relapsed prostate cancer: clinical trial results with alpha-N-acetylgalactosamine-O-serine/threonine conjugate vaccine. J Clin Oncol. 21:4292–4298. 2003. View Article : Google Scholar
30	Fernandez C, Gregory WF, Loke P and Maizels RM: Full-length-enriched cDNA libraries from Echinococcus granulosus contain separate populations of oligo-capped and trans-spliced transcripts and a high level of predicted signal peptide sequences. Mol Biochem Parasitol. 122:171–180. 2002.PubMed/NCBI
31	Coïc YM, Lan CL, Neumann JM, Jamin N and Baleux F: Slightly modifying pseudoproline dipeptides incorporation strategy enables solid phase synthesis of a 54 AA fragment of caveolin-1 encompassing the intramembrane domain. J Pept Sci. 16:98–104. 2010.
32	Lo-Man R, Vichier-Guerre S, Perraut R, et al: A fully synthetic therapeutic vaccine candidate targeting carcinoma-associated Tn carbohydrate antigen induces tumor-specific antibodies in nonhuman primates. Cancer Res. 64:4987–4994. 2004. View Article : Google Scholar
33	Rosa DS, Ribeiro SP and Cunha-Neto E: CD4⁺ T cell epitope discovery and rational vaccine design. Arch Immunol Ther Exp. 58:121–130. 2010.
34	Lo-Man R, Vichier-Guerre S, Bay S, Deriaud E, Cantacuzene D and Leclerc C: Antitumor immunity provided by a synthetic multiple antigenic glycopeptide displaying a tri-Tn glycotope. J Immunol. 166:2849–2854. 2001. View Article : Google Scholar : PubMed/NCBI
35	Singhal AK: Histo-blood group antigens in cancer. Semin Cancer Biol. 2:379–388. 1991.PubMed/NCBI
36	Singh SK, Streng-Ouwehand I, Litjens M, et al: Characterization of murine MGL1 and MGL2 C-type lectins: distinct glycan specificities and tumor binding properties. Mol Immunol. 46:1240–1249. 2009. View Article : Google Scholar : PubMed/NCBI
37	Hubert P, Heitzmann A, Viel S, et al: Antibody-dependent cell cytotoxicity synapses form in mice during tumor-specific antibody immunotherapy. Cancer Res. 71:5134–5143. 2011. View Article : Google Scholar : PubMed/NCBI
38	Quezada SA, Simpson TR, Peggs KS, et al: Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med. 207:637–650. 2010.
39	Baird JR, Byrne KT, Lizotte PH, et al: Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. J Immunol. 190:469–478. 2013. View Article : Google Scholar
40	Villegas FR, Coca S, Villarrubia VG, et al: Prognostic significance of tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung Cancer. 35:23–28. 2002. View Article : Google Scholar : PubMed/NCBI
41	Malhotra A and Shanker A: NK cells: immune cross-talk and therapeutic implications. Immunotherapy. 3:1143–1166. 2011. View Article : Google Scholar : PubMed/NCBI
42	Walzer T, Dalod M, Robbins SH, Zitvogel L and Vivier E: Natural-killer cells and dendritic cells: ‘l'union fait la force’. Blood. 106:2252–2258. 2005.
43	Prestwich RJ, Errington F, Steele LP, et al: Reciprocal human dendritic cell-natural killer cell interactions induce antitumor activity following tumor cell infection by oncolytic reovirus. J Immunol. 183:4312–4321. 2009. View Article : Google Scholar
44	Gerosa F, Gobbi A, Zorzi P, et al: The reciprocal interaction of NK cells with plasmacytoid or myeloid dendritic cells profoundly affects innate resistance functions. J Immunol. 174:727–734. 2005. View Article : Google Scholar : PubMed/NCBI
45	Blalock LT, Landsberg J, Messmer M, et al: Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. Oncoimmunology. 1:287–357. 2012. View Article : Google Scholar
46	van Die I, van Stijn CM, Geyer H and Geyer R: Structural and functional analysis of glycosphingolipids of Schistosoma mansoni. Methods Enzymol. 480:117–140. 2010.PubMed/NCBI
47	Truchetet ME, Beven L, Renaudin H, et al: Potential role of Mycoplasma hominis in interleukin (IL)-17-producing CD4⁺ T-cell generation via induction of IL-23 secretion by human dendritic cells. J Infect Dis. 204:1796–1805. 2011.PubMed/NCBI
48	Gowda DC: TLR-mediated cell signaling by malaria GPIs. Trends Parasitol. 23:596–604. 2007. View Article : Google Scholar : PubMed/NCBI
49	Campos MA, Almeida IC, Takeuchi O, et al: Activation of Toll-like receptor-2 by glycosylphosphatidylinositol anchors from a protozoan parasite. J Immunol. 167:416–423. 2001. View Article : Google Scholar : PubMed/NCBI
50	Junqueira C, Guerrero AT, Galvão-Filho B, et al: Trypanosoma cruzi adjuvants potentiate T cell-mediated immunity induced by a NY-ESO-1 based antitumor vaccine. PLoS One. 7:e362452012. View Article : Google Scholar : PubMed/NCBI
51	Tarang S, Kumar S and Batra SK: Mucins and toll-like receptors: kith and kin in infection and cancer. Cancer Lett. 321:110–119. 2012. View Article : Google Scholar : PubMed/NCBI
52	Freire T, Lo-Man R, Bay S and Leclerc C: Tn glycosylation of the MUC6 protein modulates its immunogenicity and promotes the induction of Th17-biased T cell responses. J Biol Chem. 286:7797–7811. 2011. View Article : Google Scholar : PubMed/NCBI